These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29719265)

  • 1. Mutant IDH1 Promotes Glioma Formation In Vivo.
    Philip B; Yu DX; Silvis MR; Shin CH; Robinson JP; Robinson GL; Welker AE; Angel SN; Tripp SR; Sonnen JA; VanBrocklin MW; Gibbons RJ; Looper RE; Colman H; Holmen SL
    Cell Rep; 2018 May; 23(5):1553-1564. PubMed ID: 29719265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
    Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
    Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
    Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
    Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
    Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
    Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
    Gao Y; de Wit M; Struys EA; van der Linde HCZ; Salomons GS; Lamfers MLM; Willemsen R; Sillevis Smitt PAE; French PJ
    PLoS One; 2018; 13(6):e0199737. PubMed ID: 29953513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
    Chuntova P; Yamamichi A; Chen T; Narayanaswamy R; Ronseaux S; Hudson C; Tron AE; Hyer ML; Montoya M; Mende AL; Nejo T; Downey KM; Diebold D; Lu M; Nicolay B; Okada H
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35606087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
    Chen R; Nishimura MC; Kharbanda S; Peale F; Deng Y; Daemen A; Forrest WF; Kwong M; Hedehus M; Hatzivassiliou G; Friedman LS; Phillips HS
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14217-22. PubMed ID: 25225364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A vaccine targeting mutant IDH1 induces antitumour immunity.
    Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
    Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
    Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
    Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
    Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
    Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.